Fig. 6: STPNs tumor-targeting ability, bioimaging, and biosafety.

a IVIS images of tumor-bearing mice depicting tumor bioluminescence (BL) and Pu18 fluorescence (FL) after free Pu18, SPNs, and STPNs administration at different time points post-intravenous injection. b T₁-weighted MR images of orthotopic GBC-bearing nude mouse before and 1 h after intravenous injection of STPNs (top); and IVIS images of tumor-bearing mice depicting tumor bioluminescence (BL) and Pu18 fluorescence (FL) after STPNs administration at 1 h post-intravenous injection. c Healthy mice were intravenously injected once a week for a total of 5 times with 150 μL PBS or STPNs (irradiated by 980 nm laser source before injection at a power density of 2.0 W cm⁻² for 5 min) and killed at day 40 for hematological analysis (n = 3 independent experiments). d Healthy mice were intravenously injected once a week for a total of 5 times with 150 μL PBS or STPNs (irradiated by 980 nm laser source before injection at a power density of 2.0 W cm⁻² for 5 min) and killed at day 40 for blood biochemical analysis (n = 3 independent experiments). The data are represented as mean ± SD (n = 3 mice per group).